経口血糖降下薬（OAD）治療の世界市場（～2026年）

• 英文タイトル：Global Oral Antidiabetic (OAD) Treatment Market Size, Status and Forecast 2020-2026

• レポートコード：MRC2-11QY04077
• 出版社/出版日：QYResearch / 2020年11月20日
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、99ページ
• 納品方法：Eメール（納期：2~3日）
• 産業分類：ヘルスケア

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ
Enterprise License	￥1,154,400 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

当調査資料は経口血糖降下薬（OAD）治療のグローバル市場について調査・分析したレポートです。種類別（スルホニル尿素剤、ビグアニド、腸内α-グルコシダーゼ阻害剤、その他）市場規模、用途別（病院、クリニック、糖尿病治療センター、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。
・調査範囲
・エグゼクティブサマリー
・企業別経口血糖降下薬（OAD）治療の競争状況、市場シェア
・世界の経口血糖降下薬（OAD）治療市場：種類別市場規模 2015年-2020年（スルホニル尿素剤、ビグアニド、腸内α-グルコシダーゼ阻害剤、その他）
・世界の経口血糖降下薬（OAD）治療市場：種類別市場規模予測 2021年-2026年（スルホニル尿素剤、ビグアニド、腸内α-グルコシダーゼ阻害剤、その他）
・世界の経口血糖降下薬（OAD）治療市場：用途別市場規模 2015年-2020年（病院、クリニック、糖尿病治療センター、その他）
・世界の経口血糖降下薬（OAD）治療市場：用途別市場規模予測 2021年-2026年（病院、クリニック、糖尿病治療センター、その他）
・北米の経口血糖降下薬（OAD）治療市場分析：米国、カナダ
・ヨーロッパの経口血糖降下薬（OAD）治療市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアの経口血糖降下薬（OAD）治療市場分析：日本、中国、韓国、インド、オーストラリア、台湾等
・中南米の経口血糖降下薬（OAD）治療市場分析：メキシコ、ブラジル、アルゼンチン等
・中東・アフリカの経口血糖降下薬（OAD）治療市場分析：トルコ、サウジアラビア、UAE等
・企業情報（企業概要、製品概要、販売量、企業動向）
- 掲載企業（変更可能性あり）：Pfizer、Eli Lilly、Merck、Sanofi、AstraZeneca、Glenmark、Novartis、Boehringer Ingelheim、Novo Nordisk、Mannkind
・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論

Diabetic is the condition where the sugar (glucose) level is high in the blood or the production of the insulin is inadequate. Diabetes main type the very first one is Type 1 and the second is Type 2, both the diabetic are most commonly find in the current scenario, apart from this many other diabetics case are also been listed as gestational diabetes and others. Various treatment method are present in the market injection, oral and others. The mostly used method of treatment or managing the diabetes is the oral.
North America has the 44.3 million population with diabetes in 2015 according to the IDF, same as Europe have 59.8 million in 2015 according to IDF and Asia Pacific has 60% diabetic population as compared with world according to Asian Diabetes Prevention Initiative.

Market Analysis and Insights: Global Oral Antidiabetic (OAD) Treatment Market
The global Oral Antidiabetic (OAD) Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Oral Antidiabetic (OAD) Treatment Scope and Market Size
Oral Antidiabetic (OAD) Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Oral Antidiabetic (OAD) Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
Pfizer
Eli Lilly
Merck
Sanofi
AstraZeneca
Glenmark
Novartis
Boehringer Ingelheim
Novo Nordisk
Mannkind

Market segment by Type, the product can be split into
Sulphonylureas
Biguanides
Intestinal α-Glucosidase Inhibitors
Others
Market segment by Application, split into
Hospital
Clinics
Diabetics Treatment Centres
Others

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Oral Antidiabetic (OAD) Treatment Revenue
1.4 Market by Type
1.4.1 Global Oral Antidiabetic (OAD) Treatment Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Sulphonylureas
1.4.3 Biguanides
1.4.4 Intestinal α-Glucosidase Inhibitors
1.4.5 Others
1.5 Market by Application
1.5.1 Global Oral Antidiabetic (OAD) Treatment Market Share by Application: 2020 VS 2026
1.5.2 Hospital
1.5.3 Clinics
1.5.4 Diabetics Treatment Centres
1.5.5 Others
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Global Oral Antidiabetic (OAD) Treatment Market Perspective (2015-2026)
2.2 Global Oral Antidiabetic (OAD) Treatment Growth Trends by Regions
2.2.1 Oral Antidiabetic (OAD) Treatment Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Oral Antidiabetic (OAD) Treatment Historic Market Share by Regions (2015-2020)
2.2.3 Oral Antidiabetic (OAD) Treatment Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Oral Antidiabetic (OAD) Treatment Market Growth Strategy
2.3.6 Primary Interviews with Key Oral Antidiabetic (OAD) Treatment Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Oral Antidiabetic (OAD) Treatment Players by Market Size
3.1.1 Global Top Oral Antidiabetic (OAD) Treatment Players by Revenue (2015-2020)
3.1.2 Global Oral Antidiabetic (OAD) Treatment Revenue Market Share by Players (2015-2020)
3.1.3 Global Oral Antidiabetic (OAD) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Oral Antidiabetic (OAD) Treatment Market Concentration Ratio
3.2.1 Global Oral Antidiabetic (OAD) Treatment Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Oral Antidiabetic (OAD) Treatment Revenue in 2019
3.3 Oral Antidiabetic (OAD) Treatment Key Players Head office and Area Served
3.4 Key Players Oral Antidiabetic (OAD) Treatment Product Solution and Service
3.5 Date of Enter into Oral Antidiabetic (OAD) Treatment Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Oral Antidiabetic (OAD) Treatment Historic Market Size by Type (2015-2020)
4.2 Global Oral Antidiabetic (OAD) Treatment Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)
5.1 Global Oral Antidiabetic (OAD) Treatment Market Size by Application (2015-2020)
5.2 Global Oral Antidiabetic (OAD) Treatment Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Oral Antidiabetic (OAD) Treatment Market Size (2015-2020)
6.2 Oral Antidiabetic (OAD) Treatment Key Players in North America (2019-2020)
6.3 North America Oral Antidiabetic (OAD) Treatment Market Size by Type (2015-2020)
6.4 North America Oral Antidiabetic (OAD) Treatment Market Size by Application (2015-2020)

7 Europe
7.1 Europe Oral Antidiabetic (OAD) Treatment Market Size (2015-2020)
7.2 Oral Antidiabetic (OAD) Treatment Key Players in Europe (2019-2020)
7.3 Europe Oral Antidiabetic (OAD) Treatment Market Size by Type (2015-2020)
7.4 Europe Oral Antidiabetic (OAD) Treatment Market Size by Application (2015-2020)

8 China
8.1 China Oral Antidiabetic (OAD) Treatment Market Size (2015-2020)
8.2 Oral Antidiabetic (OAD) Treatment Key Players in China (2019-2020)
8.3 China Oral Antidiabetic (OAD) Treatment Market Size by Type (2015-2020)
8.4 China Oral Antidiabetic (OAD) Treatment Market Size by Application (2015-2020)

9 Japan
9.1 Japan Oral Antidiabetic (OAD) Treatment Market Size (2015-2020)
9.2 Oral Antidiabetic (OAD) Treatment Key Players in Japan (2019-2020)
9.3 Japan Oral Antidiabetic (OAD) Treatment Market Size by Type (2015-2020)
9.4 Japan Oral Antidiabetic (OAD) Treatment Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Oral Antidiabetic (OAD) Treatment Market Size (2015-2020)
10.2 Oral Antidiabetic (OAD) Treatment Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Oral Antidiabetic (OAD) Treatment Market Size by Type (2015-2020)
10.4 Southeast Asia Oral Antidiabetic (OAD) Treatment Market Size by Application (2015-2020)

11 India
11.1 India Oral Antidiabetic (OAD) Treatment Market Size (2015-2020)
11.2 Oral Antidiabetic (OAD) Treatment Key Players in India (2019-2020)
11.3 India Oral Antidiabetic (OAD) Treatment Market Size by Type (2015-2020)
11.4 India Oral Antidiabetic (OAD) Treatment Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Oral Antidiabetic (OAD) Treatment Market Size (2015-2020)
12.2 Oral Antidiabetic (OAD) Treatment Key Players in Central & South America (2019-2020)
12.3 Central & South America Oral Antidiabetic (OAD) Treatment Market Size by Type (2015-2020)
12.4 Central & South America Oral Antidiabetic (OAD) Treatment Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 Pfizer
13.1.1 Pfizer Company Details
13.1.2 Pfizer Business Overview
13.1.3 Pfizer Oral Antidiabetic (OAD) Treatment Introduction
13.1.4 Pfizer Revenue in Oral Antidiabetic (OAD) Treatment Business (2015-2020))
13.1.5 Pfizer Recent Development
13.2 Eli Lilly
13.2.1 Eli Lilly Company Details
13.2.2 Eli Lilly Business Overview
13.2.3 Eli Lilly Oral Antidiabetic (OAD) Treatment Introduction
13.2.4 Eli Lilly Revenue in Oral Antidiabetic (OAD) Treatment Business (2015-2020)
13.2.5 Eli Lilly Recent Development
13.3 Merck
13.3.1 Merck Company Details
13.3.2 Merck Business Overview
13.3.3 Merck Oral Antidiabetic (OAD) Treatment Introduction
13.3.4 Merck Revenue in Oral Antidiabetic (OAD) Treatment Business (2015-2020)
13.3.5 Merck Recent Development
13.4 Sanofi
13.4.1 Sanofi Company Details
13.4.2 Sanofi Business Overview
13.4.3 Sanofi Oral Antidiabetic (OAD) Treatment Introduction
13.4.4 Sanofi Revenue in Oral Antidiabetic (OAD) Treatment Business (2015-2020)
13.4.5 Sanofi Recent Development
13.5 AstraZeneca
13.5.1 AstraZeneca Company Details
13.5.2 AstraZeneca Business Overview
13.5.3 AstraZeneca Oral Antidiabetic (OAD) Treatment Introduction
13.5.4 AstraZeneca Revenue in Oral Antidiabetic (OAD) Treatment Business (2015-2020)
13.5.5 AstraZeneca Recent Development
13.6 Glenmark
13.6.1 Glenmark Company Details
13.6.2 Glenmark Business Overview
13.6.3 Glenmark Oral Antidiabetic (OAD) Treatment Introduction
13.6.4 Glenmark Revenue in Oral Antidiabetic (OAD) Treatment Business (2015-2020)
13.6.5 Glenmark Recent Development
13.7 Novartis
13.7.1 Novartis Company Details
13.7.2 Novartis Business Overview
13.7.3 Novartis Oral Antidiabetic (OAD) Treatment Introduction
13.7.4 Novartis Revenue in Oral Antidiabetic (OAD) Treatment Business (2015-2020)
13.7.5 Novartis Recent Development
13.8 Boehringer Ingelheim
13.8.1 Boehringer Ingelheim Company Details
13.8.2 Boehringer Ingelheim Business Overview
13.8.3 Boehringer Ingelheim Oral Antidiabetic (OAD) Treatment Introduction
13.8.4 Boehringer Ingelheim Revenue in Oral Antidiabetic (OAD) Treatment Business (2015-2020)
13.8.5 Boehringer Ingelheim Recent Development
13.9 Novo Nordisk
13.9.1 Novo Nordisk Company Details
13.9.2 Novo Nordisk Business Overview
13.9.3 Novo Nordisk Oral Antidiabetic (OAD) Treatment Introduction
13.9.4 Novo Nordisk Revenue in Oral Antidiabetic (OAD) Treatment Business (2015-2020)
13.9.5 Novo Nordisk Recent Development
13.10 Mannkind
13.10.1 Mannkind Company Details
13.10.2 Mannkind Business Overview
13.10.3 Mannkind Oral Antidiabetic (OAD) Treatment Introduction
13.10.4 Mannkind Revenue in Oral Antidiabetic (OAD) Treatment Business (2015-2020)
13.10.5 Mannkind Recent Development

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List of Tables
Table 1. Oral Antidiabetic (OAD) Treatment Key Market Segments
Table 2. Key Players Covered: Ranking by Oral Antidiabetic (OAD) Treatment Revenue
Table 3. Ranking of Global Top Oral Antidiabetic (OAD) Treatment Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Oral Antidiabetic (OAD) Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Sulphonylureas
Table 6. Key Players of Biguanides
Table 7. Key Players of Intestinal α-Glucosidase Inhibitors
Table 8. Key Players of Others
Table 9. Global Oral Antidiabetic (OAD) Treatment Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 10. Global Oral Antidiabetic (OAD) Treatment Market Size by Regions (US$ Million): 2020 VS 2026
Table 11. Global Oral Antidiabetic (OAD) Treatment Market Size by Regions (2015-2020) (US$ Million)
Table 12. Global Oral Antidiabetic (OAD) Treatment Market Share by Regions (2015-2020)
Table 13. Global Oral Antidiabetic (OAD) Treatment Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 14. Global Oral Antidiabetic (OAD) Treatment Market Share by Regions (2021-2026)
Table 15. Market Top Trends
Table 16. Key Drivers: Impact Analysis
Table 17. Key Challenges
Table 18. Oral Antidiabetic (OAD) Treatment Market Growth Strategy
Table 19. Main Points Interviewed from Key Oral Antidiabetic (OAD) Treatment Players
Table 20. Global Oral Antidiabetic (OAD) Treatment Revenue by Players (2015-2020) (Million US$)
Table 21. Global Oral Antidiabetic (OAD) Treatment Market Share by Players (2015-2020)
Table 22. Global Top Oral Antidiabetic (OAD) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Oral Antidiabetic (OAD) Treatment as of 2019)
Table 23. Global Oral Antidiabetic (OAD) Treatment by Players Market Concentration Ratio (CR5 and HHI)
Table 24. Key Players Headquarters and Area Served
Table 25. Key Players Oral Antidiabetic (OAD) Treatment Product Solution and Service
Table 26. Date of Enter into Oral Antidiabetic (OAD) Treatment Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Oral Antidiabetic (OAD) Treatment Market Size by Type (2015-2020) (Million US$)
Table 29. Global Oral Antidiabetic (OAD) Treatment Market Size Share by Type (2015-2020)
Table 30. Global Oral Antidiabetic (OAD) Treatment Revenue Market Share by Type (2021-2026)
Table 31. Global Oral Antidiabetic (OAD) Treatment Market Size Share by Application (2015-2020)
Table 32. Global Oral Antidiabetic (OAD) Treatment Market Size by Application (2015-2020) (Million US$)
Table 33. Global Oral Antidiabetic (OAD) Treatment Market Size Share by Application (2021-2026)
Table 34. North America Key Players Oral Antidiabetic (OAD) Treatment Revenue (2019-2020) (Million US$)
Table 35. North America Key Players Oral Antidiabetic (OAD) Treatment Market Share (2019-2020)
Table 36. North America Oral Antidiabetic (OAD) Treatment Market Size by Type (2015-2020) (Million US$)
Table 37. North America Oral Antidiabetic (OAD) Treatment Market Share by Type (2015-2020)
Table 38. North America Oral Antidiabetic (OAD) Treatment Market Size by Application (2015-2020) (Million US$)
Table 39. North America Oral Antidiabetic (OAD) Treatment Market Share by Application (2015-2020)
Table 40. Europe Key Players Oral Antidiabetic (OAD) Treatment Revenue (2019-2020) (Million US$)
Table 41. Europe Key Players Oral Antidiabetic (OAD) Treatment Market Share (2019-2020)
Table 42. Europe Oral Antidiabetic (OAD) Treatment Market Size by Type (2015-2020) (Million US$)
Table 43. Europe Oral Antidiabetic (OAD) Treatment Market Share by Type (2015-2020)
Table 44. Europe Oral Antidiabetic (OAD) Treatment Market Size by Application (2015-2020) (Million US$)
Table 45. Europe Oral Antidiabetic (OAD) Treatment Market Share by Application (2015-2020)
Table 46. China Key Players Oral Antidiabetic (OAD) Treatment Revenue (2019-2020) (Million US$)
Table 47. China Key Players Oral Antidiabetic (OAD) Treatment Market Share (2019-2020)
Table 48. China Oral Antidiabetic (OAD) Treatment Market Size by Type (2015-2020) (Million US$)
Table 49. China Oral Antidiabetic (OAD) Treatment Market Share by Type (2015-2020)
Table 50. China Oral Antidiabetic (OAD) Treatment Market Size by Application (2015-2020) (Million US$)
Table 51. China Oral Antidiabetic (OAD) Treatment Market Share by Application (2015-2020)
Table 52. Japan Key Players Oral Antidiabetic (OAD) Treatment Revenue (2019-2020) (Million US$)
Table 53. Japan Key Players Oral Antidiabetic (OAD) Treatment Market Share (2019-2020)
Table 54. Japan Oral Antidiabetic (OAD) Treatment Market Size by Type (2015-2020) (Million US$)
Table 55. Japan Oral Antidiabetic (OAD) Treatment Market Share by Type (2015-2020)
Table 56. Japan Oral Antidiabetic (OAD) Treatment Market Size by Application (2015-2020) (Million US$)
Table 57. Japan Oral Antidiabetic (OAD) Treatment Market Share by Application (2015-2020)
Table 58. Southeast Asia Key Players Oral Antidiabetic (OAD) Treatment Revenue (2019-2020) (Million US$)
Table 59. Southeast Asia Key Players Oral Antidiabetic (OAD) Treatment Market Share (2019-2020)
Table 60. Southeast Asia Oral Antidiabetic (OAD) Treatment Market Size by Type (2015-2020) (Million US$)
Table 61. Southeast Asia Oral Antidiabetic (OAD) Treatment Market Share by Type (2015-2020)
Table 62. Southeast Asia Oral Antidiabetic (OAD) Treatment Market Size by Application (2015-2020) (Million US$)
Table 63. Southeast Asia Oral Antidiabetic (OAD) Treatment Market Share by Application (2015-2020)
Table 64. India Key Players Oral Antidiabetic (OAD) Treatment Revenue (2019-2020) (Million US$)
Table 65. India Key Players Oral Antidiabetic (OAD) Treatment Market Share (2019-2020)
Table 66. India Oral Antidiabetic (OAD) Treatment Market Size by Type (2015-2020) (Million US$)
Table 67. India Oral Antidiabetic (OAD) Treatment Market Share by Type (2015-2020)
Table 68. India Oral Antidiabetic (OAD) Treatment Market Size by Application (2015-2020) (Million US$)
Table 69. India Oral Antidiabetic (OAD) Treatment Market Share by Application (2015-2020)
Table 70. Central & South America Key Players Oral Antidiabetic (OAD) Treatment Revenue (2019-2020) (Million US$)
Table 71. Central & South America Key Players Oral Antidiabetic (OAD) Treatment Market Share (2019-2020)
Table 72. Central & South America Oral Antidiabetic (OAD) Treatment Market Size by Type (2015-2020) (Million US$)
Table 73. Central & South America Oral Antidiabetic (OAD) Treatment Market Share by Type (2015-2020)
Table 74. Central & South America Oral Antidiabetic (OAD) Treatment Market Size by Application (2015-2020) (Million US$)
Table 75. Central & South America Oral Antidiabetic (OAD) Treatment Market Share by Application (2015-2020)
Table 76. Pfizer Company Details
Table 77. Pfizer Business Overview
Table 78. Pfizer Product
Table 79. Pfizer Revenue in Oral Antidiabetic (OAD) Treatment Business (2015-2020) (Million US$)
Table 80. Pfizer Recent Development
Table 81. Eli Lilly Company Details
Table 82. Eli Lilly Business Overview
Table 83. Eli Lilly Product
Table 84. Eli Lilly Revenue in Oral Antidiabetic (OAD) Treatment Business (2015-2020) (Million US$)
Table 85. Eli Lilly Recent Development
Table 86. Merck Company Details
Table 87. Merck Business Overview
Table 88. Merck Product
Table 89. Merck Revenue in Oral Antidiabetic (OAD) Treatment Business (2015-2020) (Million US$)
Table 90. Merck Recent Development
Table 91. Sanofi Company Details
Table 92. Sanofi Business Overview
Table 93. Sanofi Product
Table 94. Sanofi Revenue in Oral Antidiabetic (OAD) Treatment Business (2015-2020) (Million US$)
Table 95. Sanofi Recent Development
Table 96. AstraZeneca Company Details
Table 97. AstraZeneca Business Overview
Table 98. AstraZeneca Product
Table 99. AstraZeneca Revenue in Oral Antidiabetic (OAD) Treatment Business (2015-2020) (Million US$)
Table 100. AstraZeneca Recent Development
Table 101. Glenmark Company Details
Table 102. Glenmark Business Overview
Table 103. Glenmark Product
Table 104. Glenmark Revenue in Oral Antidiabetic (OAD) Treatment Business (2015-2020) (Million US$)
Table 105. Glenmark Recent Development
Table 106. Novartis Company Details
Table 107. Novartis Business Overview
Table 108. Novartis Product
Table 109. Novartis Revenue in Oral Antidiabetic (OAD) Treatment Business (2015-2020) (Million US$)
Table 110. Novartis Recent Development
Table 111. Boehringer Ingelheim Business Overview
Table 112. Boehringer Ingelheim Product
Table 113. Boehringer Ingelheim Company Details
Table 114. Boehringer Ingelheim Revenue in Oral Antidiabetic (OAD) Treatment Business (2015-2020) (Million US$)
Table 115. Boehringer Ingelheim Recent Development
Table 116. Novo Nordisk Company Details
Table 117. Novo Nordisk Business Overview
Table 118. Novo Nordisk Product
Table 119. Novo Nordisk Revenue in Oral Antidiabetic (OAD) Treatment Business (2015-2020) (Million US$)
Table 120. Novo Nordisk Recent Development
Table 121. Mannkind Company Details
Table 122. Mannkind Business Overview
Table 123. Mannkind Product
Table 124. Mannkind Revenue in Oral Antidiabetic (OAD) Treatment Business (2015-2020) (Million US$)
Table 125. Mannkind Recent Development
Table 126. Research Programs/Design for This Report
Table 127. Key Data Information from Secondary Sources
Table 128. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Oral Antidiabetic (OAD) Treatment Market Share by Type: 2020 VS 2026
Figure 2. Sulphonylureas Features
Figure 3. Biguanides Features
Figure 4. Intestinal α-Glucosidase Inhibitors Features
Figure 5. Others Features
Figure 6. Global Oral Antidiabetic (OAD) Treatment Market Share by Application: 2020 VS 2026
Figure 7. Hospital Case Studies
Figure 8. Clinics Case Studies
Figure 9. Diabetics Treatment Centres Case Studies
Figure 10. Others Case Studies
Figure 11. Oral Antidiabetic (OAD) Treatment Report Years Considered
Figure 12. Global Oral Antidiabetic (OAD) Treatment Market Size YoY Growth 2015-2026 (US$ Million)
Figure 13. Global Oral Antidiabetic (OAD) Treatment Market Share by Regions: 2020 VS 2026
Figure 14. Global Oral Antidiabetic (OAD) Treatment Market Share by Regions (2021-2026)
Figure 15. Porter's Five Forces Analysis
Figure 16. Global Oral Antidiabetic (OAD) Treatment Market Share by Players in 2019
Figure 17. Global Top Oral Antidiabetic (OAD) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Oral Antidiabetic (OAD) Treatment as of 2019
Figure 18. The Top 10 and 5 Players Market Share by Oral Antidiabetic (OAD) Treatment Revenue in 2019
Figure 19. North America Oral Antidiabetic (OAD) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Europe Oral Antidiabetic (OAD) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. China Oral Antidiabetic (OAD) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Japan Oral Antidiabetic (OAD) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Southeast Asia Oral Antidiabetic (OAD) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. India Oral Antidiabetic (OAD) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Central & South America Oral Antidiabetic (OAD) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Bottom-up and Top-down Approaches for This Report
Figure 27. Data Triangulation
Figure 28. Key Executives Interviewed

以下、関連資料のご紹介

オピオイド誘発性便秘（OIC）治療の世界市場（～2026年）

Global Opioid-Induced Constipation (OIC) Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY04062 2020年11月20日 99Pages
当調査資料はオピオイド誘発性便秘（OIC）治療のグローバル市場について調査・分析したレポートです。種類別（経口、非経口（皮下注射））市場規模、用途別（ドラッグストア、独立型薬局、病院薬局）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中...

頭頸部扁平上皮がん (HNSCC)治療の世界市場（～2026年）

Global Squamous Cell Carcinoma of the Head and Neck Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY04717 2020年11月20日 128Pages
当調査資料は頭頸部扁平上皮がん (HNSCC)治療のグローバル市場について調査・分析したレポートです。種類別（唾液腺、口腔および中咽頭、鼻腔および副鼻腔、鼻咽頭、喉頭および下咽頭）市場規模、用途別（病院、専門クリニック、外来外科センター）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フラ...

化学療法薬誘発性肢端紅斑（手足症候群）治療の世界市場（～2026年）

Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY11343 2020年11月25日 92Pages
当調査資料は化学療法薬誘発性肢端紅斑（手足症候群）治療のグローバル市場について調査・分析したレポートです。種類別（鎮痛剤、抗炎症剤・抗浮腫剤、抗ヒスタミン剤、NSAID、経口/局所グルココルチコイド、ピリドキシン（ビタミンB6）、その他）市場規模、用途別（薬局・ドラッグストア、病院薬局、オンラインド...

多形性膠芽腫（GBM）治療の世界市場（～2026年）

Global Glioblastoma Multiforme Treatment (GBM) Market Size, Status and Forecast 2020-2026
MRC2-11QY12056 2020年11月25日 92Pages
当調査資料は多形性膠芽腫（GBM）治療のグローバル市場について調査・分析したレポートです。種類別（化学療法、放射線療法、遺伝子治療、分子バイオテクノロジー）市場規模、用途別（ベバコズマブ、カルムスチン、テモゾロミド）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリ...

神経精神障害・治療の世界市場（～2026年）

Global Neuropsychiatric Disorders And Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY03957 2020年11月20日 97Pages
当調査資料は神経精神障害・治療のグローバル市場について調査・分析したレポートです。種類別（変性疾患、神経症、精神病）市場規模、用途別（病院、診療所、研究センター）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オースト...

グロボイド細胞白質ジストロフィー（GLD）治療の世界市場（～2026年）

Global Globoid Cell Leukodystrophy Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY12059 2020年11月25日 93Pages
当調査資料はグロボイド細胞白質ジストロフィー（GLD）治療のグローバル市場について調査・分析したレポートです。種類別（RND-001、CMB-200、DUOC-01、その他）市場規模、用途別（病院、クリニック、研究センター）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス...

癲癇診断・治療の世界市場（～2026年）

Global Epilepsy Diagnosis & Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY11874 2020年11月25日 91Pages
当調査資料は癲癇診断・治療のグローバル市場について調査・分析したレポートです。種類別（診断（神経学的検査・血液検査・画像診断）、治療（医学・手術））市場規模、用途別（病院、クリニック）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、...

HIV診断・治療の世界市場（～2026年）

Global HIV Diagnosis & Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY12200 2020年11月25日 95Pages
当調査資料はHIV診断・治療のグローバル市場について調査・分析したレポートです。種類別（ELISA検査、唾液検査、ウイルス量検査、ウエスタンブロット、その他）市場規模、用途別（病院、クリニック）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日...

脱毛症（脱毛）治療の世界市場（～2026年）

Global Alopecia (Hair Loss)Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY13657 2020年11月30日 95Pages
当調査資料は脱毛症（脱毛）治療のグローバル市場について調査・分析したレポートです。種類別（ビタミン・サプリメント、シャンプー・コンディショナー、その他）市場規模、用途別（男性、女性、子供）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中...

髄膜炎診断・治療の世界市場（～2026年）

Global Meningitis Diagnosis and Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY12650 2020年11月25日 91Pages
当調査資料は髄膜炎診断・治療のグローバル市場について調査・分析したレポートです。種類別（血液培養、イメージング、腰椎穿刺）市場規模、用途別（病院・クリニック、診断センター）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド...

抗糖尿病薬の世界市場（～2026年） Diabetes mellitus is a kind of chronic comprehensive disease mainly caused by glucose metabolism disorder due to absolute or relative deficiency of insulin or decreased insulin sensitivity of target cells. The occurrence of type 2 diabetes mellitus is a combination of peripheral insulin resistance a…
口腔がん治療の世界市場（～2026年） Oral cancer, also known as mouth cancer, is a type of head and neck cancer and is any cancerous tissue growth located in the oral cavity. It may arise as a primary lesion originating in any of the tissues in the mouth, by metastasis from a distant site of origin, or by extension from a neighboring a…
多嚢胞性卵巣症候群治療の世界市場（～2026年） Polycystic ovary syndrome is a set of symptoms due to elevated androgens in females. Signs and symptoms of polycystic ovary syndrome nclude irregular or no menstrual periods, heavy periods, excess body and facial hair, acne, pelvic pain, difficulty getting pregnant and patches of thick, darker, velv…
心房細動（SPAF）治療における脳卒中予防の世界市場（～2026年） Atrial fibrillation (AF) now a days has become a common and serious condition affecting almost 1-2% of the total population of age group 65 years and above. Increase in the aging population leads to increase in the prevalence further leads to increase rick of premature death. Market Analysis and Ins…
口腔粘膜炎の世界市場（～2026年） Mucositis occurs when cancer treatments break down the rapidly divided epithelial cells lining the gastro-intestinal tract (which goes from the mouth to the anus), leaving the mucosal tissue open to ulceration and infection. Mucosal tissue, also known as mucosa or the mucous membrane, lines all body…